Benzinga's Top Upgrades, Downgrades For September 2, 2020

Upgrades

For Zillow Group Inc ZG, Deutsche Bank upgraded the previous rating of Hold to the current rating Buy. In the second quarter, Zillow Gr showed an EPS of $0.41, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $88.82 and a 52-week-low of $18.65. Zillow Gr closed at $88.26 at the end of the last trading period.
Berenberg upgraded the previous rating for Southwest Airlines Co LUV from Hold to Buy. For the second quarter, Southwest Airlines had an EPS of $2.67, compared to year-ago quarter EPS of $1.37. The current stock performance of Southwest Airlines shows a 52-week-high of $58.83 and a 52-week-low of $22.46. Moreover, at the end of the last trading period, the closing price was at $37.92.
RBC Capital upgraded the previous rating for Equitable Holdings Inc EQH from Sector Perform to Outperform. For the second quarter, Equitable Holdings had an EPS of $1.00, compared to year-ago quarter EPS of $1.14. The current stock performance of Equitable Holdings shows a 52-week-high of $27.30 and a 52-week-low of $9.89. Moreover, at the end of the last trading period, the closing price was at $21.10.

Downgrades

According to Credit Suisse, the prior rating for Youdao Inc DAO was changed from Outperform to Neutral. In the second quarter, Youdao earned $0.33. The stock has a 52-week-high of $47.70 and a 52-week-low of $12.01. At the end of the last trading period, Youdao closed at $32.19.
Loop Capital downgraded the previous rating for Wanda Sports Group Co Ltd WSG from Buy to Hold. Wanda Sports Group Co earned $0.05 in the second quarter, compared to $0.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.35 and a 52-week-low of $1.36. Wanda Sports Group Co closed at $2.11 at the end of the last trading period.
According to Berenberg, the prior rating for American Airlines Group Inc AAL was changed from Hold to Sell. In the second quarter, American Airlines Group showed an EPS of $7.82, compared to $1.82 from the year-ago quarter. The current stock performance of American Airlines Group shows a 52-week-high of $31.67 and a 52-week-low of $8.25. Moreover, at the end of the last trading period, the closing price was at $13.10.
For Delta Air Lines Inc DAL, Berenberg downgraded the previous rating of Buy to the current rating Hold. Delta Air Lines earned $4.43 in the second quarter, compared to $2.35 in the year-ago quarter. At the moment, the stock has a 52-week-high of $62.48 and a 52-week-low of $17.51. Delta Air Lines closed at $30.71 at the end of the last trading period.

Initiations

With a current rating of Outperform, Barrington Research initiated coverage on Franchise Group Inc FRG. The price target seems to have been set at $33.00 for Franchise Group. Franchise Group earned $0.53 in the second quarter. At the moment, the stock has a 52-week-high of $27.49 and a 52-week-low of $5.75. Franchise Group closed at $25.09 at the end of the last trading period.
For Ionis Pharmaceuticals Inc IONS, Benchmark initiated coverage, by setting the current rating at Hold. In the second quarter, Ionis Pharmaceuticals showed an EPS of $0.23, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $67.31 and a 52-week-low of $39.32. At the end of the last trading period, Ionis Pharmaceuticals closed at $54.27.
With a current rating of Hold, Truist Securities initiated coverage on DraftKings Inc DKNG. The price target seems to have been set at $39.00 for DraftKings. DraftKings earned $0.55 in the second quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $44.79 and a 52-week-low of $18.00. At the end of the last trading period, DraftKings closed at $36.93.
William Blair initiated coverage on Nautilus Inc NLS with an Outperform rating. For the second quarter, Nautilus had an EPS of $0.56, compared to year-ago quarter EPS of $0.25. The stock has a 52-week-high of $15.91 and a 52-week-low of $1.20. At the end of the last trading period, Nautilus closed at $13.85.
With a current rating of Neutral, Baird initiated coverage on BioTelemetry Inc BEAT. The price target seems to have been set at $43.00 for BioTelemetry. In the second quarter, BioTelemetry showed an EPS of $0.35, compared to $0.53 from the year-ago quarter. The current stock performance of BioTelemetry shows a 52-week-high of $55.85 and a 52-week-low of $27.35. Moreover, at the end of the last trading period, the closing price was at $39.75.
With a current rating of Buy, Jefferies initiated coverage on New Oriental Education & Technology Group Inc EDU. The price target seems to have been set at $175.00 for New Oriental Education. New Oriental Education earned $0.30 in the fourth quarter, compared to $0.60 in the year-ago quarter. The current stock performance of New Oriental Education shows a 52-week-high of $153.02 and a 52-week-low of $102.01. Moreover, at the end of the last trading period, the closing price was at $151.01.
With a current rating of Outperform, Baird initiated coverage on Hill-Rom Holdings Inc HRC. The price target seems to have been set at $115.00 for Hill-Rom Holdings. For the third quarter, Hill-Rom Holdings had an EPS of $1.95, compared to year-ago quarter EPS of $1.23. At the moment, the stock has a 52-week-high of $117.68 and a 52-week-low of $72.29. Hill-Rom Holdings closed at $92.50 at the end of the last trading period.
With a current rating of Outperform, Baird initiated coverage on Inspire Medical Systems Inc INSP. The price target seems to have been set at $130.00 for Inspire Medical Systems. In the second quarter, Inspire Medical Systems showed an EPS of $0.88, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $124.65 and a 52-week-low of $40.53. At the end of the last trading period, Inspire Medical Systems closed at $123.89.
With a current rating of Neutral, Baird initiated coverage on iRhythm Technologies Inc IRTC. The price target seems to have been set at $220.00 for iRhythm Technologies. In the second quarter, iRhythm Technologies showed an EPS of $0.75, compared to $0.46 from the year-ago quarter. The current stock performance of iRhythm Technologies shows a 52-week-high of $232.58 and a 52-week-low of $56.24. Moreover, at the end of the last trading period, the closing price was at $226.70.
Baird initiated coverage on Intuitive Surgical Inc ISRG with a Neutral rating. The price target for Intuitive Surgical is set to $700.00. In the second quarter, Intuitive Surgical showed an EPS of $1.11, compared to $3.25 from the year-ago quarter. The current stock performance of Intuitive Surgical shows a 52-week-high of $742.44 and a 52-week-low of $360.50. Moreover, at the end of the last trading period, the closing price was at $741.57.
Baird initiated coverage on LivaNova PLC LIVN with an Outperform rating. The price target for LivaNova is set to $55.00. For the second quarter, LivaNova had an EPS of $0.15, compared to year-ago quarter EPS of $0.70. The current stock performance of LivaNova shows a 52-week-high of $87.45 and a 52-week-low of $33.40. Moreover, at the end of the last trading period, the closing price was at $46.05.
Baird initiated coverage on Masimo Corp MASI with an Outperform rating. The price target for Masimo is set to $260.00. Masimo earned $0.85 in the second quarter, compared to $0.76 in the year-ago quarter. At the moment, the stock has a 52-week-high of $258.00 and a 52-week-low of $139.36. Masimo closed at $223.65 at the end of the last trading period.
With a current rating of Outperform, Baird initiated coverage on Nevro Corp NVRO. The price target seems to have been set at $160.00 for Nevro. For the second quarter, Nevro had an EPS of $1.21, compared to year-ago quarter EPS of $0.91. The current stock performance of Nevro shows a 52-week-high of $148.05 and a 52-week-low of $65.05. Moreover, at the end of the last trading period, the closing price was at $143.38.
Jefferies initiated coverage on BioXcel Therapeutics Inc BTAI with a Buy rating. The price target for BioXcel Therapeutics is set to $82.00. BioXcel Therapeutics earned $1.06 in the second quarter, compared to $0.54 in the year-ago quarter. The stock has a 52-week-high of $71.50 and a 52-week-low of $3.76. At the end of the last trading period, BioXcel Therapeutics closed at $40.75.